– USA, MA – Akili, Inc. (NASDAQ: AKLI), a leading digital medicine company, today announced the appointment of Mary Hentges to its board of directors, effective October 25, 2022.
“We are honored and excited to have Mary join our board of directors. Her experience scaling high-growth, industry-defining businesses, and her passion for bold missions that have the potential to change society, will be invaluable as we work to establish the first prescription digital therapeutic in routine clinical care,” said co-founder and CEO, Eddie Martucci.
Mary Hentges will also serve as chair of the Audit Committee and a member of the Compensation Committee.
About Mary Hentges
Mary Hentges has extensive executive-level and financial experience with public and private companies. Hentges’ proven track record serving as CFO at several high-growth companies will support Akili as it enters its next phase of growth with the commercialization of its flagship product, EndeavorRx.
Mary Hentges has held the roles of interim CFO at ShotSpotter, Inc., a precision-policing solutions company; CFO of YapStone, Inc., a digital payments provider; CFO of CBS Interactive, an internet media company; and CFO of PayPal, Inc., a global digital financial services provider. Before those positions, Hentges worked in various roles in finance at Agilent Technologies, Inc., and Hewlett-Packard, Inc., diversified technology companies. Additionally, Hentges holds several board positions, including director and audit committee member, Upstart Holdings, Inc; director and finance committee chair, nominating and governance committee member and executive committee member, Kaiser Permanente Bernard J. Tyson School of Medicine; and director and investment committee member, ASU Foundation.
“I look forward to supporting Akili and its mission of igniting new hope for the millions of people living with cognitive health issues,” said Mary Hentges. “Akili is inspirational in its effort to create a new class of digital medicines delivered through captivating video game experiences. The potential of providing some relief from cognitive issues while avoiding the potential side effects of compound-based medicines is a game changer for patients, parents, and physicians.”
About Akili
Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to target the brain directly establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences.
For more information: https://www.akiliinteractive.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.